Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Company Overview - Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases with significant unmet medical needs, including Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD) [3] Upcoming Events - The company will host a webcast on November 12, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and provide a business update for the third quarter ended September 30, 2024 [1][2] Product Development - Belite's lead candidate, Tinlarebant, is an oral therapy aimed at reducing the accumulation of toxins in the eye and is currently being evaluated in multiple studies: a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for adolescent STGD1 subjects, as well as a Phase 3 study (PHOENIX) for subjects with GA [3]